Target Name: MUC22
NCBI ID: G100507679
Other Name(s): G4 | PBMUCL1 | Panbronchiolitis-related mucin-like protein 1 | Mucin 22, transcript variant 2 | MUC22_HUMAN | Panbronchiolitis related mucin-like 1 | MUC22 variant 2 | Mucin-22 | panbronchiolitis-related mucin-like protein 1 | Mucin 22 | Mucin-22 (isoform 2) | mucin 22

MUC22: A Drug Target / Disease Biomarker

MUC22 is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a member of the major histocompatibility complex (MHC) class I molecules, which are responsible for presenting antigens from the body's immune system to T-cells. MUC22 has been identified as a potential drug target due to its unique structure and its involvement in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

MUC22 is composed of a transmembrane region and a cytoplasmic tail that consists of a single amino acid, alanine. The transmembrane region is made up of two distinct domains: a N-terminal alpha-helix and a C-terminal alpha-sheet. The alpha-helix is a loop of 11 amino acids that is responsible for the protein's stability and localization to the cell surface. The alpha-sheet is a region of 12 amino acids that is involved in the protein's structure and function.

MUC22 is a glycoprotein, which means that it consists of both protein and carbohydrate components. The protein component of MUC22 consists of 154 amino acids, while the carbohydrate component consists of 30 amino acids. The protein is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is also expressed in the placenta, which supports the development and growth of new tissues.

MUC22 has been involved in various physiological processes in the body, including immune response, inflammation, and tissue repair. It is a key regulator of the immune response, as it helps to present antigens from the body's immune system to T-cells. MUC22 has also been involved in the regulation of inflammation, as it has been shown to play a role in the production of pro-inflammatory cytokines.

In addition to its involvement in the immune response and inflammation, MUC22 has also been linked to a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, MUC22 has been shown to be overexpressed in various types of cancer, which may contribute to the development and progression of these diseases. It has also been linked to a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Finally, MUC22 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Due to its involvement in these diseases and its potential as a drug target, MUC22 has received a great deal of interest in recent years. Researchers have been studying its structure and function in order to understand its role in these diseases, as well as its potential as a drug.

One approach to studying MUC22 is through the use of techniques such as biochemical assays and live cell assays. These methods can be used to study the protein's structure and function in different contexts, including its role in the immune response and inflammation. For example, researchers have used biochemical assays to study the effects of drugs on MUC22's stability and localization to the cell surface. They have also used live cell assays to study the protein's role in the immune response, as well as its involvement in the regulation of inflammation.

Another approach to studying MUC22 is through the use of animal models. Researchers have used mice and other animals to study the effects of drugs on MUC22's expression and function in different contexts, including its role in the immune response and inflammation. For example, they have used these models to study the effects of drugs on the growth and progression of cancer, as well as the development and progression of autoimmune disorders.

In addition to these approaches, researchers have also been studying the potential clinical applications of MUC22 as a drug target. This

Protein Name: Mucin 22

More Common Targets

MUC3A | MUC3B | MUC4 | MUC5AC | MUC5B | MUC6 | MUC7 | MUC8 | Mucin | MUCL1 | MUCL3 | MUL1 | Multisubunit histone acetyltransferase complex | MUPP | MUS81 | Muscarinic Acetylcholine Receptor (mAChR) | MUSK | MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2